ARS Pharmaceuticals, Inc. SPRY 深 沪
等待开盘 02-07 09:30:00 美东时间
9.8907
+0.221
+2.28%
华盛通- 最 高13.15
- 今 开9.87
- 成交量 18.40万股
- 最 低 9.60
- 昨 收 9.67
- 总市值 0
- 52周最高 18.89
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 6.66
- 委 比 95.44%
- 总股本 --
- 历史最高 63.41
- 量 比 0.66
- 振 幅 36.71%
- 历史最低 0.00
- 每 手 1
- 风险率 2.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application
Aquestive Therapeutics shares fall after the FDA flags deficiencies in its Anaphylm allergy drug application, raising approval delay concerns despite the review remaining active.
01-10 00:28
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
2025-11-10 19:12
Earnings Outlook For ARS Pharmaceuticals
ARS Pharmaceuticals (NASDAQ:SPRY) is set to give its latest quarterly earnings ...
2025-11-08 02:04
ARS Pharmaceuticals Launches Get Neffy On Us Commercial Program
ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to
2025-11-04 21:04
Analyst Ratings For ARS Pharmaceuticals
In the preceding three months, 4 analysts have released ratings for ARS Pharmac...
2024-09-10 02:00
Cantor Fitzgerald Reiterates Overweight on ARS Pharmaceuticals, Maintains $30 Price Target
Cantor Fitzgerald analyst Josh Schimmer reiterates ARS Pharmaceuticals (NASDAQ:SPRY) with a Overweight and maintains $30 price target.
2024-09-10 00:15
ARS Pharmaceuticals Launches Pre-Ordering Services For neffy To Help Patients Access The Treatment For Type I Allergic Reactions, Including Anaphylaxis
Patients can request a prescription from their existing healthcare provider, or meet with a physician virtually, to request a prescription for neffy ahead of product availability expected by late September Visit neffy.com to pre-order and access comprehensive patient assistance programs available ...
2024-09-04 20:19
ARS Pharmaceuticals Says EC Approves EURneffy for Emergency Treatment of Allergic Reactions
10:45 AM EDT, 08/26/2024 (MT Newswires) -- ARS Pharmaceuticals (SPRY) said Monday the European Commission has approved EURneffy for the emergency treatment of allergic reactions including anaphylaxis. The adrenaline nasal spray will serve as the first needle-free treatment for severe allergies in th...
2024-08-26 22:45
ARS Pharmaceuticals' EURneffy Adrenaline Nasal Spray Approved By European Commission For Emergency Treatment Of Severe Allergic Reactions
Marking First New Delivery Method In EU In Over 30 Years
2024-08-26 21:30
